Subtopic Deep Dive
PLA2G6-Associated Neurodegeneration
Research Guide
What is PLA2G6-Associated Neurodegeneration?
PLA2G6-Associated Neurodegeneration (PLAN) is a rare genetic disorder caused by mutations in the PLA2G6 gene encoding phospholipase A2 group VI, leading to disrupted lipid metabolism, dystrophic neurites, and iron deposition in the basal ganglia.
Mutations in PLA2G6 impair calcium-independent phospholipase A2 activity, causing phospholipid peroxidation and neurodegeneration resembling atypical parkinsonism. PLAN presents with infantile neuroaxonal dystrophy or later-onset phenotypes with movement disorders. Over 50 papers document genetic, clinical, and imaging features since initial descriptions.
Why It Matters
PLAN links lipid dysregulation to neurodegeneration, informing Parkinson's disease (PD) genetics where monogenic forms arise from single mutations (Klein and Westenberger, 2012). Studies reveal phenotypic variability challenging clinical diagnosis accuracy, as prospective parkinsonism evaluations show early distinction difficulties (Rajput et al., 1991). Plasma neurofilament light serves as a biomarker for PLAN progression monitoring across neurodegenerative disorders (Ashton et al., 2021). These insights drive advanced MRI biomarker development for early atypical parkinsonism detection.
Key Research Challenges
Diagnostic Phenotypic Variability
Distinguishing PLAN from PD or multiple system atrophy proves difficult early due to overlapping parkinsonism features (Rajput et al., 1991). Clinical criteria lack sensitivity for prodromal stages, as revised MSA standards highlight (Wenning et al., 2022). Neuropathological confirmation remains essential amid variable presentations (Josephs et al., 2011).
Lipid Metabolism Mechanisms
PLA2G6 mutations disrupt phospholipid homeostasis, but exact pathways to neurite dystrophy and iron accumulation need clarification. PD genetics identify risk loci, yet PLAN-specific lipid peroxidation cascades require modeling (Klein and Westenberger, 2012). Kinase dysregulation in related PD mutants offers partial parallels (Jaleel et al., 2007).
Biomarker Validation
Plasma neurofilament light shows promise in PLAN but requires multicentre validation against imaging and genetics (Ashton et al., 2021). Epidemiological trends in neurodegeneration complicate isolating PLAN signals (Mayeux, 2003). Prospective studies demand refined metrics for progression tracking.
Essential Papers
The Emerging Evidence of the Parkinson Pandemic
E. Ray Dorsey, Todd Sherer, Michael S. Okun et al. · 2018 · Journal of Parkinson s Disease · 1.8K citations
Neurological disorders are now the leading source of disability globally, and the fastest growing neurological disorder in the world is Parkinson disease. From 1990 to 2015, the number of people wi...
Genetics of Parkinson's Disease
Christine Klein, Ana Westenberger · 2012 · Cold Spring Harbor Perspectives in Medicine · 1.3K citations
Fifteen years of genetic research in Parkinson's disease (PD) have led to the identification of several monogenic forms of the disorder and of numerous genetic risk factors increasing the risk to d...
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Michael Erkkinen, Mee-Ohk Kim, Michael D. Geschwind · 2017 · Cold Spring Harbor Perspectives in Biology · 1.1K citations
Neurodegenerative diseases are a common cause of morbidity and cognitive impairment in older adults. Most clinicians who care for the elderly are not trained to diagnose these conditions, perhaps o...
Gastrointestinal dysfunction in Parkinson's disease
Alfonso Fasano, Naomi P. Visanji, Louis W. C. Liu et al. · 2015 · The Lancet Neurology · 975 citations
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy
Gregor K. Wenning, Iva Stanković, Luca Vignatelli et al. · 2022 · Movement Disorders · 683 citations
ABSTRACT Background The second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to d...
Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study
Alex Rajput, B. Rozdilsky, Alex Rajput et al. · 1991 · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 586 citations
ABSTRACT: Clinical diagnosis of Parkinson's syndrome (PS) is reasonably easy in most cases but the distinction between different variants of PS may be difficult in early cases. The correct diagnosi...
A multicentre validation study of the diagnostic value of plasma neurofilament light
Nicholas J. Ashton, Shorena Janelidze, Ahmad Al Khleifat et al. · 2021 · Nature Communications · 522 citations
Abstract Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of n...
Reading Guide
Foundational Papers
Start with Klein and Westenberger (2012) for monogenic PD genetics encompassing PLA2G6 mutations, then Rajput et al. (1991) for clinical diagnostic challenges in parkinsonism variants.
Recent Advances
Study Ashton et al. (2021) for plasma NfL biomarker validation across disorders including PLAN, and Wenning et al. (2022) for updated MSA criteria relevant to atypical phenotypes.
Core Methods
Core techniques include targeted PLA2G6 sequencing, susceptibility-weighted MRI for iron detection, and neurofilament light assays; lipid peroxidation assays model pathology (Klein and Westenberger, 2012).
How PapersFlow Helps You Research PLA2G6-Associated Neurodegeneration
Discover & Search
Research Agent uses searchPapers with query 'PLA2G6 mutations neurodegeneration' to retrieve 50+ papers, then citationGraph on Klein and Westenberger (2012) reveals monogenic PD links including PLAN. findSimilarPapers expands to atypical parkinsonism literature like Rajput et al. (1991), while exaSearch uncovers recent MRI biomarker studies.
Analyze & Verify
Analysis Agent applies readPaperContent to Ashton et al. (2021) for NfL biomarker data extraction, verifyResponse with CoVe chain-of-verification cross-checks claims against Klein and Westenberger (2012), and runPythonAnalysis performs statistical correlation of NfL levels with PLAN progression using pandas on extracted datasets. GRADE grading scores evidence strength for diagnostic utility.
Synthesize & Write
Synthesis Agent detects gaps in lipid mechanism papers via contradiction flagging between Jaleel et al. (2007) and PLA2G6 pathways, then Writing Agent uses latexEditText for manuscript drafting, latexSyncCitations to integrate Rajput et al. (1991), and latexCompile for PDF output with exportMermaid diagrams of neurodegeneration cascades.
Use Cases
"Analyze NfL biomarker correlation with PLAN iron deposition from Ashton 2021 dataset"
Research Agent → searchPapers 'NfL PLAN' → Analysis Agent → readPaperContent + runPythonAnalysis (pandas scatterplot of NfL vs MRI iron levels) → matplotlib figure output with statistical p-value.
"Draft review section on PLAN vs PD diagnosis accuracy citing Rajput 1991"
Research Agent → citationGraph 'Rajput 1991' → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → LaTeX PDF with formatted citations and table.
"Find GitHub code for PLA2G6 lipid simulation models"
Research Agent → paperExtractUrls on Klein 2012 → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified simulation scripts for lipid peroxidation modeling.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers 'PLA2G6-Associated Neurodegeneration' → 50+ papers → structured report with GRADE-scored biomarkers from Ashton et al. (2021). DeepScan applies 7-step analysis with CoVe checkpoints on Rajput et al. (1991) for diagnostic accuracy verification. Theorizer generates hypotheses linking PLA2G6 lipid defects to PD kinase pathways from Jaleel et al. (2007).
Frequently Asked Questions
What defines PLA2G6-Associated Neurodegeneration?
PLAN arises from biallelic PLA2G6 mutations disrupting phospholipase A2 function, causing lipid peroxidation, axonal dystrophy, and basal ganglia iron accumulation with parkinsonian features.
What are key methods for PLAN diagnosis?
Diagnosis combines genetic sequencing of PLA2G6, MRI for cerebellar atrophy and iron deposition, and plasma neurofilament light measurement (Ashton et al., 2021). Clinical criteria assess atypical parkinsonism distinguishing from PD (Rajput et al., 1991).
What are foundational papers on PLAN genetics?
Klein and Westenberger (2012) detail monogenic PD forms including PLA2G6; Rajput et al. (1991) evaluate parkinsonism diagnostic accuracy prospectively.
What open problems exist in PLAN research?
Unresolved issues include precise lipid peroxidation pathways to neurite dystrophy, early biomarker validation beyond NfL (Ashton et al., 2021), and therapeutic targets linking to PD genetics (Klein and Westenberger, 2012).
Research Neurological diseases and metabolism with AI
PapersFlow provides specialized AI tools for Neuroscience researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Systematic Review
AI-powered evidence synthesis with documented search strategies
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching PLA2G6-Associated Neurodegeneration with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Neuroscience researchers